A PHASE 2, RANDOMIZED, OPEN-LABEL, CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RAPCABTAGENE AUTOLEUCEL VERSUS COMPARATOR IN PARTICIPANTS WITH SEVERE ACTIVE GRANULOMATOSIS WITH POLYANGIITIS (GPA) OR MICROSCOPIC POLYANGIITIS (MPA)

Registry ID

CYTB323I12201

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

NOVARTIS PHARMACEUTICALS CANADA INC

Last update

2025-03-27

Conditions

• GRANULOMATOSIS WITH POLYANGIITIS (GPA)

Related clinical trials

• SAFE EFFECTIVE THERAPY WITH LOW-DOSE GLUCOCORTICOID IN ANCA-ASSOCIATED VASCULITIS (SAFE-LOW) TRIAL
• A RANDOMIZED, CONTROLLED STUDY TO EVALUATE LNP023 (IPTACOPAN) IN PATIENTS WITH ACTIVE ANCA-ASSOCIATED VASCULITIS
• A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF NS-229 IN THE TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS

View on source registry